v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash Flows Used in Operating Activities    
Net loss $ (12,872) $ (2,602)
Adjustment to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 32 13
Amortization of intangible assets 91 43
Amortization of right-of-use asset 53 10
Non-cash interest expense, net of interest income 145 94
Stock-based compensation 455 5,792
Impairment of intangible assets 531
Change in fair value of convertible notes payable (12,882)
Loss on extinguishment of debt 421 6,732
Warrant issuance expense 2,016
Change in fair value of warrant liability (503) (398)
Other 3 (123)
Changes in operating assets and liabilities:    
Accounts receivable and other receivables 157 (143)
Inventories (19) 373
Prepaid expenses and other current assets (594) (841)
Other assets 348 (7)
Accounts payable (624) 1,722
Related party payables (51) (60)
Accrued expenses and other current liabilities (4,892) (496)
Accrued interest 67 243
Deferred revenue 46 (13)
Operating lease obligation (52) (8)
Net Cash Used in Operating Activities (15,242) (2,551)
Cash Flows (Used in) Provided by Investing Activities    
Purchase of property and equipment (45) (7)
Cash received in purchase of Inpixon 2,968
Purchase of intangible asset (3)
Net Cash (Used in) Provided by Investing Activities (45) 2,958
Cash Provided by Financing Activities    
Net proceeds from sale of common stock and pre-funded warrants via public offerings 21,651
Net proceeds from ATM stock offering 1,667
Net proceeds from the exercise of liability classified warrants 1  
Net proceeds from promissory notes 378
Net proceeds from loan from Inpixon (prior to merger) 1,012
Redemption of Series 9 preferred stock (1,427)
Repayments of promissory notes (2,719)
Net Cash Provided by Financing Activities 19,173 1,390
Effect of Foreign Exchange Rate on Changes on Cash 17 (1)
Net Increase in Cash and Cash Equivalents 3,903 1,796
Cash and Cash Equivalents - Beginning of period 4,105 5
Cash and Cash Equivalents - End of period 8,008 1,801
Supplemental Disclosure of cash flow information:    
Interest 281 2
Income Taxes 4
Non-cash investing and financing activities    
Common shares issued for conversion of debt and accrued interest 750 9,614
Issuance of common shares for merger consideration, net of cash received 22,637
Right-of-use asset obtained in exchange for lease liability 394
Capital contribution - forgiveness of related party payable 380
Series 9 preferred stock dividend accrued $ 61

Source

10-Q PDF
XBRL